MedTrace Logo

Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics

NCT00692341 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-04-11

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effects of mild and moderate impairment of hepatic function on the single-dose pharmacokinetics, safety and tolerability of AG-013736.

Conditions

  • Hepatic Insufficiency

Interventions

DRUG

AG-013736

Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.

DRUG

AG-013736

Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.

DRUG

AG-013736

Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00692341 on ClinicalTrials.gov